Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
12.02 USD | +0.29% | -0.58% | +75.95% |
Jun. 05 | Y-mAbs Therapeutics, Inc. Appoints Norman LaFrance as Chief Development Officer | CI |
Jun. 01 | Y-mAbs Therapeutics, Inc. Announces Publication of Preclinical GD2-SADA Data | CI |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+75.95% | 526M | |
+18.39% | 125B | |
+13.58% | 108B | |
-7.29% | 24.21B | |
+2.07% | 22.78B | |
-10.79% | 17.96B | |
-41.74% | 16.43B | |
-13.23% | 16.37B | |
+1.54% | 13.58B | |
+27.52% | 11.66B |
- Stock Market
- Equities
- YMAB Stock
- News Y-mAbs Therapeutics, Inc.
- Transcript : Y-mAbs Therapeutics, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 05